�����ƽ��

Dr. Daniela Mora Ortiz is a Product Manager for the Hematology portfolio at �����ƽ�� Technologies. She earned her medical degree in Mexico City and completed her specialization in Hematology and Hemotherapy at Hospital Vall d’Hebron in Barcelona, Spain, where she gained clinical experience in hematological diseases, hematopoietic stem cell transplantation, and blood bank activities. Following her clinical training, she conducted research on pluripotent stem cell differentiation toward hematopoietic lineages and lung differentiation, developing expertise in stem cell biology and translational research. Since joining �����ƽ�� in 2017, Dr. Mora Ortiz has held roles in education, lab management, scientific support, and product management, providing training, advanced technical support, troubleshooting, and consultation to researchers worldwide. She has worked extensively with hematopoietic, epithelial, and organoid culture systems, including intestinal, hepatic, pancreatic, neural, and lung models, as well as air–liquid interface (ALI) cultures. In her current role, she leads and supports cross-functional initiatives in hematology and cell and gene therapy, bridging clinical insight, scientific expertise, and product strategy to enable researchers to translate discoveries from bench to bedside. She is passionate about advancing hematology and cell and gene therapy research and about empowering scientists to translate innovation into meaningful clinical impact.

Dr. Jackie Damen is the Senior Scientific Advisor of the Hematopoiesis department at �����ƽ�� Technologies. In a career spanning over 30 years, Dr. Damen has acquired extensive experience in the field of hematopoiesis, where her key strengths lie in stem cell biology, protein biochemistry, and cell signaling, especially in the area of erythropoietin. In her role as Senior Scientific Advisor, Hematopoiesis, as well as her past experience as Director of Contract Assay Services at �����ƽ��, Dr. Damen has conducted hundreds of customized studies involving the CFU assay to provide numerous pharmaceutical and biotechnology clients with solutions to their drug development questions. Dr. Damen actively participates in several educational initiatives, regularly providing online talks and presentations of topical interest at high profile conferences such as the Society of Toxicology Annual Meeting and the International Society for Cell & Gene Therapy (ISCT). At �����ƽ��, Dr. Damen has been involved in customer training in hematopoietic stem cell biology and colony identification since 2002.

Dr. Karina McQueen joined the Research and Development group at �����ƽ�� Technologies in 2005 after completing a postdoctoral fellowship at Stanford with Dr. Peter Parham. With her MHC/HLA background, it was a natural transition to move from studying killer cell immunoglobulin-like receptors (KIR) on NK cells to developing products that make routine testing in an HLA laboratory less laborious. For the past 20 years, Karina has developed numerous EasySep™ kits for use in crossmatch assays and chimerism testing.

Dr. Tina Jeng joined Contract Assay Services at �����ƽ�� Technologies in 2012, where she was responsible for designing and executing customized projects to evaluate the effects of candidate therapeutics, including small molecule compounds and biologics, for more than 150 biotech and pharmaceutical customers across the globe. In her current role as Hematology Scientist at �����ƽ��, she provides product and scientific support to customers, distributors, and staff globally. She also contributes to various internal and external training programs for products, protocols, and workflows in the hematology portfolio.